Core Viewpoint - The announcement highlights the initiation of the global multicenter Phase II clinical trial for CS2009, a novel tri-specific antibody targeting PD-1, VEGFA, and CTLA-4, with the first patient enrolled in Australia [1] Group 1: Clinical Trial Progress - The Phase II clinical trial for CS2009 is actively enrolling patients in Australia and China, with plans to expand to the United States in the future [1] - The first patient has been enrolled in Australia, marking a significant milestone in the trial's progress [1] Group 2: Product Overview - CS2009 is a tri-specific antibody developed independently by the company, designed to target PD-1, VEGFA, and CTLA-4, aiming to achieve multi-dimensional anti-tumor effects [1] - The antibody has the potential to be a first-in-class or best-in-class treatment due to its differentiated molecular design [1] Group 3: Mechanism and Indications - CS2009 is capable of reactivating exhausted tumor-infiltrating T cells and has neutralizing capabilities against VEGF comparable to existing anti-VEGF antibodies [1] - The product has a broad disease coverage, including but not limited to non-small cell lung cancer, small cell lung cancer, liver cancer, gastric cancer, ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and esophageal cancer [1]
基石药业-B：CS2009(PD-1/VEGF/CTLA-4三特异性抗体)II期临床试验于澳大利亚完成首例患者入组